CTOs on the Move

NeoChord

www.neochord.com

 
NeoChord is a venture backed medical device company that has developed a proprietary device which allows mitral valve repair to be performed on a beating heart through a 2- to 3-inch incision between the ribs in patients with severe mitral valve regurgitation (MR). In contrast, most mitral valve repair procedures are performed through a 3 to 10 inch chest incision (sternotomy) that involves cutting through the sternum, opening the rib cage, stopping the heart and placing the patient on cardio-pulmonary bypass (CPB).
  • Number of Employees: 25-100
  • Annual Revenue: $0-1 Million

Executives

Name Title Contact Details

Funding

NeoChord raised $10M on 09/20/2017
NeoChord raised $25M on 11/06/2018

Similar Companies

UltraRAD Corp

UltraRAD Corp is a West Berlin, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

NarrativeDx

NarrativeDx is the artificial intelligence platform for patient experience. Our SaaS platform is the market leader in transforming hospitals` clinical outcomes by extracting data trends and gaining visibility into the patient experience. We help hospital leaders and care providers understand and improve their institution`s patient experience, drive patient referrals, increase hospital revenue, and boost hospital reputations.

Accord BioPharma

Foresee is a Taiwan and US-based biopharmaceutical company listed on the Taipei Exchange (6576.TWO). Foresee`s R&D efforts are focused in two key areas, namely its unique stabilized injectable formulation (SIF) depot delivery technology with derived drug products targeting specialty markets, and secondly its transformative preclinical and clinical first-in-class NCE programs targeting rare and severe disease areas with high unmet needs. Foresee`s product portfolio includes late stage and early stage programs. CAMCEVI® 42 mg is now approved in the U.S. and under regulatory review in the EU. Additionally, U.S. and EU regulatory submissions are in preparation for CAMCEVI® 21 mg. FP-025 – a highly selective oral MMP-12 inhibitor targeting inflammatory and fibrotic diseases, currently in Phase 2/3 studies, including a Phase 2/3 study for COVID-19 virus-induced acute respiratory distress syndrome (ARDS). FP-045 – a highly selective oral small molecule allosteric activator of ALDH2, a mitochondrial enzyme, for which a Phase 1b/2 study is currently planned for Fanconi Anemia.

Diller Medical Inc

Diller Medical Inc is a Bluffton, OH-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Canyon House and Crescent Villa

Canyon House and Crescent Villa is a Sunnyvale, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.